U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H64N4O12
Molecular Weight 877.0307
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RIFAPENTINE

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N5CCN(CC5)C6CCCC6)=C(O)C4=C3C2=O

InChI

InChIKey=WDZCUPBHRAEYDL-GZAUEHORSA-N
InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1

HIDE SMILES / InChI
Molecular Formula C47H64N4O12
Molecular Weight 877.0307
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/21024lbl.pdf http://www.drugbank.ca/drugs/DB01201

PRIFTIN® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. Rifapentine is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. And it acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency. Rifapentine has shown higher bacteriostatic and bactericidal activities especially against intracellular bacteria growing in human monocyte-derived macrophages.

Approval Year

1998
123
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
PRIFTIN

Approved Use

is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.05 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
600 mg 1 times / 3 days steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25.8 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ISONIAZID
ISONIAZID
 RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
319.54 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
600 mg 1 times / 3 days steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
817 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ISONIAZID
ISONIAZID
 RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.19 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
600 mg 1 times / 3 days steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
16.6 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ISONIAZID
ISONIAZID
 RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf
600 mg 1 times / 3 days steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAPENTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg/kg 1 times / day multiple, oral
MTD
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22472995
healthy
Health Status: healthy
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/22472995
Sources:
https://pubmed.ncbi.nlm.nih.gov/22472995
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Disc. AE: Hepatotoxicity...
Other AEs: Hyperbilirubinemia, Discoloration urine...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Other AEs:
Hyperbilirubinemia
Discoloration urine
Clostridium difficile colitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Disc. AE: Hepatitis, ALT increased...
AEs leading to
discontinuation/dose reduction:
Hepatitis (0.28%)
ALT increased (0.28%)
AST increased (0.28%)
LDH increased (0.28%)
Bilirubin increased (0.28%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Clostridium difficile colitis
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Discoloration urine
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Hyperbilirubinemia
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Hepatotoxicity Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
ALT increased 0.28%
Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
AST increased 0.28%
Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Bilirubin increased 0.28%
Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Hepatitis 0.28%
Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
LDH increased 0.28%
Disc. AE
600 mg 2 times / week multiple, oral
Recommended
Dose: 600 mg, 2 times / week
Route: oral
Route: multiple
Dose: 600 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
1087
inhibitor
2438

inducer
440
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
2057

CYP2E1
1060

UGT1A1
246

UGT1A4
98

UGT1A6
136

UGT1A9
148

UGT2B7
197

UGT2B15
84

CYP3A
227

CYP2B6
926

CYP2C8
1057

CYP1A2
2153
CYP2C8
198

OATP1B1
29

OATP1B3
8

MRP1
74

MRP2
146
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP3A
317
 no
UGT1A6
171
 no
UGT1A9
155
 no
UGT2B15
84
 no
UGT1A4
100
 yes [IC50 230 uM]
UGT2B7
210
 yes [IC50 357 uM]
UGT1A1
303
 yes [IC50 70 uM]
CYP2C8
1117
 yes
CYP2C9
2497
 yes
CYP3A4
2633
 yes
MRP1
232
 yes
MRP2
625
 yes
OATP1B1
1095
 yes
OATP1B3
970
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:45304
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45304
ChemicalBook
CB7482119
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7482119
eMolecules
30100394
https://www.emolecules.com/cgi-bin/more?vid=30100394
MolPort
MolPort-006-132-325
https://www.molport.com/shop/molecule-link/MolPort-006-132-325
MolPort
MolPort-035-395-832
https://www.molport.com/shop/molecule-link/MolPort-035-395-832
Selleck Chemicals
Rifapentine(Priftin)
http://www.selleckchem.com/products/Rifapentine(Priftin).html
ZINC
ZINC000169621228
http://zinc15.docking.org/substances/ZINC000169621228
PubMed

PubMed

TitleDatePubMed
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015-06
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013-11
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine.
2011-12-01
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
2011-09-15
Structure and anti-TB activity of trachylobanes from the liverwort Jungermannia exsertifolia ssp. cordifolia.
2010-04-23
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
2008-07
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
2006-10
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
2003-01
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
2001-12
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.
2000-10
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
2000-10
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
2000-05
In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.
2000-01
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
1999-10
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
1999-09
Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.
1999-01
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
1998-07
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
1997-05
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.
1996-12
Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
1996-11
[In vitro anti-MAC activities of new quinolones in focus (1)].
1996-09
Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
1996-06
How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?
1996-02
New drugs for tuberculosis.
1995-09
Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.
1995-09
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis.
1995-02
Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.
1994-11
Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.
1994-10
Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice.
1994-08
Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.
1994-02
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
1993-12
Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.
1993-03
Activity of rifapentine against Mycobacterium avium infection in beige mice.
1992-05
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
1992-01
In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.
1991-10
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
1991-07
In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).
1990-06
Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
1990-03
New antibacterial drugs for the treatment of mycobacterial disease in man.
1988-07
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
1987-09
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.
1987-06
Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex.
1987
[In-vitro antimycobacterial activity of rifapentine (comparison with rifampicin)].
1986-12
Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare.
1985-09
Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin.
1982-08
Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
1981-08
Patents

Patents

US 5306715 A
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: PRIFTIN should be administered at a dose of 600 mg twice weekly for two months as directly observed therapy (DOT), with an interval of no less than 3 consecutive days (72 hours) between doses, in combination with other anti- tuberculosis drugs as part of an appropriate regimen which includes daily companion drugs such as isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA).
600 mg twice weekly for two months
Route of Administration: Oral
In Vitro Use Guide
In a comparison of in vitro properties of rifapentine (RIF), the minimal inhibitory concentration of RIF against Mycobacterium tuberculosis in Tween-albumin liquid medium was usually 0.02 micrograms/ml; the bactericidal activity against a log phase culture was slightly less than that of RMP and the recovery after pulsed exposures to 1 microgram/ml of RIF lasting 6, 24 and 96 h was identical for the two rifamycins.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:16:46 GMT 2025
Edited
by admin
on Wed Apr 02 09:16:46 GMT 2025
Record UNII
XJM390A33U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFAPENTINE
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
PRIFITIN
Preferred Name English
KTC-1
Code English
RIFAPENTINE [VANDF]
Common Name English
R-773
Code English
DL-473
Code English
R-77-3
Code English
rifapentine [INN]
Common Name English
Rifapentine [WHO-DD]
Common Name English
RIFAPENTINE [MART.]
Common Name English
RIFAMYCIN AF/ACPP
Common Name English
MDL 473
Code English
RIFAPENTINE [MI]
Common Name English
3-((4-CYCLOPENTYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN
Common Name English
RIFAMYCIN, 3-(((4-CYCLOPENTYL-1-PIPERAZINYL)IMINO)METHYL)-
Common Name English
3-(((4-CYCLOPENTYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN
Common Name English
RIFAPENTIN
Common Name English
RIFAPENTINE [ORANGE BOOK]
Common Name English
PRIFTIN
Brand Name English
ANTIBIOTIC DL-473IT
Code English
RIFAPENTINE [USAN]
Common Name English
MDL-473
Code English
3-[N-(4-Cyclopentyl-1-piperazinyl)formimidoyl]rifamycin
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C280
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
NDF-RT N0000007911
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
FDA ORPHAN DRUG 89495
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
NDF-RT N0000007911
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
NDF-RT N0000007911
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
WHO-VATC QJ04AB05
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
NDF-RT N0000175501
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
FDA ORPHAN DRUG 89695
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
LIVERTOX NBK548547
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
EU-Orphan Drug EU/3/10/750
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
FDA ORPHAN DRUG 89595
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
WHO-ATC J04AB05
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
NDF-RT N0000007911
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
Code System Code Type Description
EVMPD
SUB10311MIG
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
SMS_ID
100000080562
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
MERCK INDEX
m9614
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C66516
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
WIKIPEDIA
Rifapentine
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
FDA UNII
XJM390A33U
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
DRUG BANK
DB01201
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
DAILYMED
XJM390A33U
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
INN
4765
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
LACTMED
Rifapentine
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
CHEBI
45304
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
EPA CompTox
DTXSID8041115
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
RXCUI
35617
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY RxNorm
USAN
X-15
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
CAS
61379-65-5
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
ECHA (EC/EINECS)
262-743-9
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
DRUG CENTRAL
2378
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
PUBCHEM
135403821
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
ChEMBL
CHEMBL1660
Created by admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
The bound concentration increased slightly (,2%) as the concentration of 14C-rifapentine increased from 0.5 to 10 mg/ml. At concentrations above 10 mg/ml, protein binding did not appear to vary with increasing concentration.
BINDING
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INDUCER
Structure of RIFAPENTINE
EXCRETED UNCHANGED
FECAL
Structure of RIFAPENTINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A5
METABOLIC ENZYME -> INDUCER
Structure of RIFAPENTINE
EXCRETED UNCHANGED
URINE
Related Record Type Details
Structure of 25-DESACETYLRIFAPENTINE
METABOLITE -> PARENT
URINE
Structure of 3-FORMYLRIFAMYCIN
METABOLITE -> PARENT
FECAL
Structure of 3-FORMYL-25-DESACETYLRIFAMYCIN
METABOLITE -> PARENT
FECAL
Structure of 25-DESACETYLRIFAPENTINE
METABOLITE -> PARENT
FECAL
Related Record Type Details
Structure of RIFAPENTINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966